Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
CBL0137 decreased the viability of a panel of MLL-r leukemia cell lines (n = 12) and xenograft cells derived from patients with MLL-r acute lymphoblastic leukemia (ALL, n = 3) in vitro with submicromolar IC50s.
|
31325323 |
2020 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Infant acute lymphoblastic leukemias (ALL) are rare hematological malignancies occurring in children younger than 1 year of age, most frequently associated with KMT2A rearrangements (KMT2A-r).
|
31515871 |
2020 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
KMT2A rearrangements are highly pathogenic leukaemic drivers, reflected by the high incidence of KMT2Ar ALL in infants, who carry few leukaemia-associated cooperative mutations.
|
31705930 |
2020 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
ALL related to prior cytotoxic therapy (t-ALL) appears to be a distinct entity when compared to the de novo ALL, with characteristics including older age at the time of onset, female predominance and leukemia genetics enriched with KMT2A (MLL) gene rearrangement and chromosomes 5/7 abnormalities.
|
31235377 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We report BU PK data on HSCT conditioning for infants with KMT2A-gene-rearrangement-positive acute lymphoblastic leukemia (MLL-r ALL).
|
31201644 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, defining mechanisms underlying MLL-r ALL maintenance is critical for developing effective therapy.
|
31395602 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Except for one case with biallelic KMT2A (MLL) breaks, all cases analyzed by FISH lacked the most common translocations defining molecular subsets of lymphoblastic leukemia/lymphomas.
|
30578714 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A few breakpoints detected in the SAR region were mapped within the AF9 region that was previously reported to translocate with the mixed lineage leukaemia (MLL) gene in an acute lymphoblastic leukaemia (ALL) patient.
|
30646906 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
MLL rearrangements are translocation mutations that cause both acute lymphoblastic leukemia and acute myeloid leukemia (AML).
|
31405949 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
After referral to our clinic, tests of the morphology, immunology, cytogenetics, and molecular biology of his bone marrow led to a diagnosis of MLL-AF4 fusion positive B-cell ALL.
|
31192927 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Although KMT2A rearrangement is the predominant genetic signature in infantile B-ALL, disease course is heterogenous, behaving more aggressively in younger infants.
|
30188223 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Multiple mice engrafted with MLL-r ALL remained disease free for more than 1 year after treatment.
|
31821784 |
2019 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
However, since this disease is highly represented in the infant and paediatric population, this review will focus on this demographic group and summarise the biological, clinical and epidemiological knowledge on B cell acute lymphoblastic leukaemia of four well characterised subtypes: t(4;11) MLL-AF4, t(12;21) ETV6-RUNX1, t(1;19) E2A-PBX1 and t(9;22) BCR-ABL1.
|
28819864 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Frozen/thawed CARCIK-CD19 remained fully functional both in vitro and in an established patient-derived xenograft (PDX) of MLL-ENL rearranged acute lymphoblastic leukemia (ALL).
|
29641322 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
These combined data demonstrate that panobinostat cross-inhibits multiple epigenetic pathways, ultimately contributing to its highly efficacious targeting of MLL-rearranged ALL.
|
28690313 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
NRAS mutations were associated with a higher frequency of hyperdiploidy (P = 0.01) and lower frequency of ETV6-RUNX1 (P < 0.01), whereas KRAS mutations were associated with younger age (P < 0.01), a higher frequency of KMT2A rearranged (P < 0.01) but no significant difference if infants with ALL were excluded, and inferior event-free survival (66.6% vs. 80.5%, P = 0.04).
|
28853218 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Such factors as younger age than 2 years old, MLL/AF4 fusion gene, poor response to prednisone, or no complete remission (CR) on TP3 were poor prognostic parameters in predicting the outcome in childhood ALL with MLL gene rearrangement treated with CCLG-ALL 2008 protocol.
|
30280786 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
MLL+ALL has a unique gene profile distinguishable from other types of ALL and AML, and should be investigated separately in responses to biological active agents including chemokine inhibitors.
|
30453100 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overall, our data demonstrate that wild-type MLL1 is a regulator of pre-BCR signaling and B cell differentiation and further suggest that targeting its function in pro-B cell ALL may be more broadly effective than previously anticipated.
|
29351999 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53).
|
28819280 |
2018 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Childhood acute lymphoblastic leukaemia (ALL) with MLL rearrangement (MLL-r) is an aggressive disease still associated with a high mortality rate.
|
29056538 |
2017 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings show how amlexanox degrades the resistance of <i>KMT2A/AFF1</i>-positive ALL to TNFα by downregulating S100A6 expression, with immediate potential implications for improving clinical management of <i>KMT2A/AFF1</i>-positive ALL.<i></i>.
|
28646023 |
2017 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
|
27122129 |
2017 |
Acute lymphocytic leukemia
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast, infant ALL without KMT2A-R is more similar to ALL of older children and survival has improved modestly with intensification of chemotherapy.
|
27841777 |
2017 |
Acute lymphocytic leukemia
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Deregulation of the epigenome is an important pathogenetic mechanism in acute lymphoblastic leukemia (ALL) with lysine (K)-specific methyltransferase 2A rearrangement (KMT2Ar).
|
27786413 |
2017 |